

Assay Advantage (Vaccine Analytics) Ltd

trading as Assay Advantage Vaccine (Analytics) Ltd

Unaudited Abbreviated Accounts

for the Year Ended 31 March 2016

Mansell & Co
Chartered Certified Accountants
5 Ducketts Wharf
South Street
Bishops Stortford
Hertfordshire
CM23 3AR

Assay Advantage (Vaccine Analytics) Ltd
trading as Assay Advantage Vaccine (Analytics) Ltd
Contents

Abbreviated Balance Sheet	<u>1</u> to <u>2</u>
Notes to the Abbreviated Accounts	<u>3</u> to <u>4</u>

Assay Advantage (Vaccine Analytics) Ltd

trading as Assay Advantage Vaccine (Analytics) Ltd

(Registration number: 05807728)

Abbreviated Balance Sheet as at 31 March 2016

	Note	2016 £	2015 £
Fixed assets			
Intangible assets	<u>2</u>	300	300
Tangible assets	<u>2</u>	1,565	140
		<hr/>	<hr/>
		1,865	440
		<hr/>	<hr/>
Current assets			
Debtors		19,674	56,797
Cash at bank and in hand		424,711	345,633
		<hr/>	<hr/>
		444,385	402,430
		<hr/>	<hr/>
Creditors: Amounts falling due within one year		(47,209)	(37,212)
		<hr/>	<hr/>
Net current assets		397,176	365,218
		<hr/>	<hr/>
Total assets less current liabilities		399,041	365,658
		<hr/>	<hr/>
Accruals and deferred income		(1,386)	(1,100)
		<hr/>	<hr/>
Net assets		397,655	364,558
		<hr/>	<hr/>
Capital and reserves			
Called up share capital	<u>3</u>	1,000	1,000
Profit and loss account		396,655	363,558
		<hr/>	<hr/>
Shareholders funds		397,655	364,558

For the year ending 31 March 2016 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

Approved by the Board on 26 July 2016 and signed on its behalf by:

.....
D r J W S a v o p o u l o s
Company secretary and director

.....
D r R S a v o p o u l o s
Director

The notes on pages 3 to 4 form an integral part of these financial statements.
Page 1

Assay Advantage (Vaccine Analytics) Ltd

trading as Assay Advantage Vaccine (Analytics) Ltd

(Registration number: 05807728)

Abbreviated Balance Sheet as at 31 March 2016

.....

D r
Company secretary and director

J W

S a v o p o u l o s

.....

D r
Director

R

S a v o p o u l o s

The notes on pages 3 to 4 form an integral part of these financial statements.

Page 2

Assay Advantage (Vaccine Analytics) Ltd
trading as Assay Advantage Vaccine (Analytics) Ltd
Notes to the Abbreviated Accounts

1 Accounting policies

Basis of preparation

The full financial statements, from which these abbreviated accounts have been extracted, have been prepared under the historical cost convention.

Turnover

Turnover represents amounts chargeable, net of value added tax, in respect of the sale of goods and services to customers.

Revenue recognition

Revenue is recognised to the extent that the company obtains the right to consideration in exchange for its performance. Revenue is measured at the fair value of the consideration received, excluding discounts, rebates, VAT and other sales tax or duty.

Goodwill

Positive goodwill is capitalised, classified as an asset on the balance sheet and amortised on a straight line basis over its useful economic life. It is reviewed for impairment at the end of the first full financial year following the acquisition and in other periods if events or changes in circumstances indicate that the carrying value may not be recoverable.

Intangible assets

Intangible assets are stated in the balance sheet at cost less accumulated amortisation and impairment. They are amortised on a straight line basis over their estimated useful lives.

Depreciation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Asset class	Depreciation method and rate
Plant and machinery	33% straight line
Computer equipment	33% straight line

Foreign currency

Transactions in foreign currencies are recorded at the exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated at the closing rates at the balance sheet date. All exchange differences are included in the profit and loss account.

Pensions

The company operates a defined contribution pension scheme. Contributions are recognised in the profit and loss account in the period in which they become payable in accordance with the rules of the scheme.

Assay Advantage (Vaccine Analytics) Ltd

trading as Assay Advantage Vaccine (Analytics) Ltd Notes to the Abbreviated Accounts

2 Fixed assets

	Intangible assets £	Tangible assets £	Total £
Cost			
At 1 April 2015	300	4,981	5,281
Additions	-	2,197	2,197
At 31 March 2016	300	7,178	7,478
Depreciation			
At 1 April 2015	-	4,841	4,841
Charge for the year	-	772	772
At 31 March 2016	-	5,613	5,613
Net book value			
At 31 March 2016	300	1,565	1,865
At 31 March 2015	300	140	440

3 Share capital

Allotted, called up and fully paid shares

2016		2015	
No.	£	No.	£

Ordinary Shares of £1 each	1,000	1,000	1,000	1,000
----------------------------	-------	-------	-------	-------

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.